Johnson & Johnson: U.S. FDA Expands Indication for Impella Heart Pumps to Treat Pediatric Patients
December 13, 2024
December 13, 2024
NEW BRUNSWICK, New Jersey, Dec. 13 -- Johnson and Johnson issued the following news release:
* * *
Impella 5.5 and Impella CP are the first left-sided, minimally invasive temporary mechanical circulatory support options for pediatric patients with symptomatic ADHF and cardiogenic shock
* * *
Danvers, Mass. - December 12, 2024 - Physicians have a new treatment option for many of the sickest pediatric patients with heart failure and cardiogenic s . . .
* * *
Impella 5.5 and Impella CP are the first left-sided, minimally invasive temporary mechanical circulatory support options for pediatric patients with symptomatic ADHF and cardiogenic shock
* * *
Danvers, Mass. - December 12, 2024 - Physicians have a new treatment option for many of the sickest pediatric patients with heart failure and cardiogenic s . . .